Lupin Receives EIR from U.S. FDA for Pithampur Unit-1 Facility

Lupin Limited has announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its Pithampur Unit-1 facility. The inspection, conducted from September 16 to September 27, 2024, concluded with the facility receiving a classification of Voluntary Action Indicated (VAI). Nilesh Gupta, Managing Director of Lupin, expressed satisfaction with the outcome, emphasizing the company's commitment to maintaining high-quality standards across all manufacturing sites. This development is expected to enhance Lupin's operational capabilities in the global market.

Source: Business Standard, CNBC TV18